Brand/Generic Settlements: DoJ Asks Second Circuit To Review Its Standards
This article was originally published in The Pink Sheet Daily
Executive Summary
If the court reverses its position, it would intensify the existing splits between the circuits and could prompt the Supreme Court to finally take up the issue.
You may also be interested in...
Legal News, In Brief: Copaxone, AngioMax, Cipro, Botox, OxyContin
Teva Wins Ruling On Copaxone Patents
Legal News, In Brief: Copaxone, AngioMax, Cipro, Botox, OxyContin
Teva Wins Ruling On Copaxone Patents
Patent Settlements: 2nd Circuit Okays Bayer's Cipro Deal But Doesn't Want To
While the U.S. Court of Appeals for the Second Circuit found that a reverse settlement agreement involving Bayer's antibiotic Cipro did not violate antitrust laws, it invited the plaintiffs to seek a reexamination of the case by the full court